nach oben

Journal of Clinical Immunology

Erschienen in:

01.11.2009

Immunological Challenges of Cardiac Transplantation: The need for Better Animal Models to Answer Current Clinical Questions

verfasst von: Jennifer R. Wehner, Craig N. Morrell, E. Rene Rodriguez, Robert L. Fairchild, William M. Baldwin III

Erschienen in: Journal of Clinical Immunology | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

In the last decade, two advances have shifted attention from cellular rejection to antibody-mediated rejection (AMR) of cardiac transplants. First, more sensitive diagnostic tests for detection of AMR have been developed. Second, improvements in immunosuppression have made severe acute cellular rejection uncommon, but have had less effect on AMR.

Discussion

Antibodies can contribute to graft rejection by activation of complement, by activation of vascular endothelial and smooth muscle cells, and by activation of neutrophils, macrophages or natural killer cells. Because acute rejection is a risk factor for chronic rejection in all types of organ transplants, it is has been proposed that AMR can cause chronic rejection.

Conclusion

Small animal models need to be developed to gain further insights into AMR and the role of antibodies in chronic graft arteriopathy. This article reviews the current clinical data and existing mouse models for AMR.

Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953;172(4379):603–6.CrossRefPubMed

Borel JF, Meszaros J. Skin transplantation in mice and dogs. Effect of cyclosporin A and dihydrocyclosporin C. Transplantation. 1980;29(2):161–2.PubMedCrossRef

Tuzcu EM, Kapadia SR, Sachar R, Ziada KM, Crowe TD, Feng J, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol. 2005;45(9):1538–42.CrossRefPubMed

Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria—an addition to the banff 97 classification of renal allograft rejection. Am J Transplant. 2003;3(6):708–14.CrossRefPubMed

Mengel M, Bogers J, Bosmans JL, Seron D, Moreso F, Carrera M, et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant. 2005;5(5):1050–6.CrossRefPubMed

Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens. 2002;11(6):609–18.CrossRefPubMed

Haas M, Rahman MH, Racusen LC, Kraus ES, Bagnasco SM, Segev DL, et al. C4d and C3d staining in biopsies of ABO-and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant. 2006;6(8):1829–40.CrossRefPubMed

Crespo-Leiro MG, Veiga-Barreiro A, Domenech N, Paniagua MJ, Pinon P, Gonzalez-Cuesta M, et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am J Transplant. 2005;5(10):2560–4.CrossRefPubMed

Rodriguez ER, Skojec DV, Tan CD, Zachary AA, Kasper EK, Conte JV, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant. 2005;5(11):2778–85.CrossRefPubMed

10.

Smith RN, Brousaides N, Grazette L, Saidman S, Semigran M, Disalvo T, et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant. 2005;24:1202–10.CrossRefPubMed

11.

Tan CD, Sokos GG, Pidwell DJ, Smedira NG, Gonzalez-Stawinski GV, Taylor DO, et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant. 2009;9(9):2075–84.CrossRefPubMed

12.

Minami K, Murata K, Lee C-Y, Fox-Talbot K, Wasowska B, Pescovitz M, et al. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant. 2006;6(5):923–32.CrossRefPubMed

13.

Platt JL. C4d and the Fate of Organ Allografts. J Am Soc Nephrol. 2002;13:2417–9.CrossRefPubMed

14.

Baldwin WM III, Kasper EK, Zachary AA, Wasowska BA, Rodriguez ER. Beyond C4d: other complement related diagnostic approaches to antibody-mediated rejection. Am J Transplant. 2004;4:311–8.CrossRefPubMed

15.

Lidington EA, Haskard DO, Mason JC. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood. 2000;96(8):2784–92.PubMed

16.

Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood. 1999;94(5):1673–82.PubMed

17.

Mason JC, Steinberg R, Lidington EA, Kinderlerer AR, Ohba M, Haskard DO. Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A. J Biol Chem. 2004;279(40):41611–8.CrossRefPubMed

18.

Bian H, Reed EF. Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. J Immunol. 1999;163(2):1010–8.PubMed

19.

Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A. 2007;104(4):1301–6.CrossRefPubMed

20.

Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol. 2008;180(4):2357–66.PubMed

21.

Lee C-Y, Reynolds M, Garyu J, Baldwin WM III, Wasowska BA. The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation. 2007;84:1324–34.CrossRefPubMed

22.

Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b–9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med. 1994;179:985–92.CrossRefPubMed

23.

Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b–9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989;264(15):9053–60.PubMed

24.

Morrell CN, Murata K, Swaim AM, Mason E, Martin TV, Thompson LE, et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res. 2008;102(7):777–85.CrossRefPubMed

25.

Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science New York, NY. 1996;271(5247):348–50.

26.

Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science New York, NY. 2006;313(5787):670–73.

27.

Wang H, Jiang J, Liu W, Kubelik D, Chen G, Gies D, et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation. 2005;79(9):1121–7.CrossRefPubMed

28.

Wang H, Arp J, Liu W, Faas SJ, Jiang J, Gies DR, et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol. 2007;179(7):4451–63.PubMed

29.

Xu Q. Stem cells and transplant arteriosclerosis. Circ Res. 2008;102(9):1011–24.CrossRefPubMed

30.

Minami E, Laflamme MA, Saffitz JE, Murry CE. Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation. 2005;112(19):2951–8.PubMed

31.

Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13(8):952–61.CrossRefPubMed

32.

Taylor DO, Edwards LB, Boucek MM, Trulock EP, Aurora P, Christie J, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report—2007. J Heart Lung Transplant. 2007;26(8):769–81.CrossRefPubMed

33.

Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18(4):1046–56.CrossRefPubMed

34.

Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin WM 3rd. Antibody and complement in transplant vasculopathy. Circ Res. 2007;100(2):191–203.CrossRefPubMed

35.

Armengol MP, Juan M, Lucas-Martin A, Fernandez-Figueras MT, Jaraquemada D, Gallart T, et al. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol. 2001;159(3):861–73.PubMed

36.

Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A. 1996;93(1):221–5.CrossRefPubMed

37.

Zarkhin V, Li L, Sarwal M. "To B or not to B?" B-cells and graft rejection. Transplantation. 2008;85(12):1705–14.CrossRefPubMed

38.

Mengel M, Reeve J, Bunnag S, Einecke G, Sis B, Mueller T, et al. Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am J Transplant. 2009;9(1):169–78.CrossRefPubMed

39.

Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, et al. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis and rheumatism. 2008;58(11):3574–84.CrossRefPubMed

40.

Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol. 2008;172(6):1650–63.CrossRefPubMed

41.

Qian Z, Hu W, Liu J, Sanfilippo F, Hruban RH, Baldwin WM III. Accelerated graft arteriosclerosis in cardiac transplants: complement activation promotes progression of lesions from medium to large arteries. Transplantation. 2001;72(5):900–6.CrossRefPubMed

42.

Qian Z, Lee CY, Murata K, Liu J, Fox-Talbot K, Wasowska BA, et al. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation. 2006;82(7):857–64.CrossRefPubMed

43.

Murata K, Fox-Talbot K, Qian Z, Takahashi K, Stahl GL, Baldwin WM III, et al. Synergistic deposition of C4d by complement and non-complement activating antibodies in cardiac transplants. Am J Transpl. 2007;7(11):2605–14.CrossRef

44.

Nozaki T, Amano H, Bickerstaff A, Orosz CG, Novick AC, Tanabe K, et al. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol. 2007;179(8):5238–45.PubMed

45.

Wasowska BA, Qian Z, Cangello DL, Behrens E, Van Tran K, Layton JL, et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation. 2001;71:727–36.CrossRefPubMed

46.

Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwin WM, Wasowska BA. Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant. 2004;4(3):326–34.CrossRefPubMed

47.

Uehara S, Chase C, Cornell L, Madsen J, Russell P, Colvin R. Chronic cardiac transplant arteriopathy in mice: Relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transpl. 2007;7:57–65.CrossRef

48.

Jindra PT, Hsueh A, Hong L, Gjertson D, Shen XD, Gao F, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol. 2008;180(4):2214–24.PubMed

49.

Morrell CN, Sun H, Swaim AM, Baldwin WM III. Platelets, an Inflammatory Force in Transplantation. Am J Transplant. 2007;7:2447–54.CrossRefPubMed

50.

Kirk AD, Morrell CN, Baldwin WM 3rd. Platelets influence vascularized organ transplants from start to finish. Am J Transplant. 2009;9(1):14–22.CrossRefPubMed

51.

Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial Gene Expression in Kidney Transplants with Alloantibody Indicates Antibody-Mediated Damage Despite Lack of C4d Staining. Am J Transplant 2009 (in press).

52.

Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts II. Importance of humoral immunity. J Immunol. 1994;152:5135–41.PubMed

53.

Ota H, Fox-Talbot K, Hu W, Qian Z, Sanfilippo F, Hruban RH, et al. Terminal complement components mediate release of von Willebrand factor and adhesion of platelets in arteries of allografts. Transplantation. 2005;79(3):276–81.CrossRefPubMed

54.

Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res. 2009;104(4):541–9.CrossRefPubMed

55.

Siow RC, Churchman AT. Adventitial growth factor signalling and vascular remodelling: potential of perivascular gene transfer from the outside-in. Cardiovascular research. 2007;75(4):659–68.CrossRefPubMed

Titel: Immunological Challenges of Cardiac Transplantation: The need for Better Animal Models to Answer Current Clinical Questions
verfasst von: Jennifer R. Wehner
Craig N. Morrell
E. Rene Rodriguez
Robert L. Fairchild
William M. Baldwin III
Publikationsdatum: 01.11.2009
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 6/2009
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-009-9334-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2009

Specific Immunotherapy to Birch Allergen Does not Enhance Suppression of Th2 Cells by CD4+CD25+ Regulatory T Cells During Pollen Season

Dectin-1 is Inducible and Plays an Essential Role for Mycobacteria-Induced Innate Immune Responses in Airway Epithelial Cells

Postmenopausal Expression Changes of Immune System-Related Genes in Human Bone Tissue

Tissue Transglutaminase Can Be Involved in Airway Inflammation of Toluene Diisocyanate-Induced Occupational Asthma

Autoimmunity, Infectious Immunity, and Atherosclerosis